These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36199061)

  • 1. A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations.
    Mahon J; Beale S; Holmes H; Arber M; Nikolayevskyy V; Alagna R; Manissero D; Dowdy D; Migliori GB; Sotgiu G; Duarte R
    BMC Pulm Med; 2022 Oct; 22(1):375. PubMed ID: 36199061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups.
    Auguste P; Tsertsvadze A; Court R; Pink J
    Tuberculosis (Edinb); 2016 Jul; 99():81-91. PubMed ID: 27450009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Screening Strategy for Latent Tuberculosis Infection (LTBI) in Contacts of Tuberculosis Patients: Systematic Review and Quality Assessment.
    Yoopetch P; Chitpim N; Jittikoon J; Udomsinprasert W; Thavorncharoensap M; Youngkong S; Praditsitthikorn N; Mahasirimongkol S; Chaikledkaew U
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.
    Auguste P; Tsertsvadze A; Pink J; Court R; McCarthy N; Sutcliffe P; Clarke A
    BMC Infect Dis; 2017 Mar; 17(1):200. PubMed ID: 28274215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study.
    Abubakar I; Lalvani A; Southern J; Sitch A; Jackson C; Onyimadu O; Lipman M; Deeks JJ; Griffiths C; Bothamley G; Kon OM; Hayward A; Lord J; Drobniewski F
    Health Technol Assess; 2018 Oct; 22(56):1-96. PubMed ID: 30334521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of cost and cost-effectiveness of different TB-screening strategies.
    Nienhaus A; Schablon A; Costa JT; Diel R
    BMC Health Serv Res; 2011 Sep; 11():247. PubMed ID: 21961888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis.
    Mancuso JD; Niebuhr DW; Frick KD; Keep LW; Anderson KM
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1223-30, i. PubMed ID: 21943850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
    Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
    Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.
    Campbell JR; Sasitharan T; Marra F
    Appl Health Econ Health Policy; 2015 Aug; 13(4):325-40. PubMed ID: 26129810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test.
    Ramos JM; Robledano C; Masiá M; Belda S; Padilla S; Rodríguez JC; Gutierrez F
    BMC Infect Dis; 2012 Jul; 12():169. PubMed ID: 22849726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Position statement on interferon-γ release assays for the detection of latent tuberculosis infection.
    Bastian I; Coulter C;
    Commun Dis Intell Q Rep; 2017 Dec; 41(4):E322-E336. PubMed ID: 29864386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country.
    Lin WC; Lin HH; Lee SS; Sy CL; Wu KS; Chen JK; Tsai HC; Chen YS
    J Microbiol Immunol Infect; 2016 Oct; 49(5):729-736. PubMed ID: 25442858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods Used in Economic Evaluations of Tuberculin Skin Tests and Interferon Gamma Release Assays for the Screening of Latent Tuberculosis Infection: A Systematic Review.
    Koufopoulou M; Sutton AJ; Breheny K; Diwakar L
    Value Health; 2016; 19(2):267-76. PubMed ID: 27021762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.
    Doan TN; Eisen DP; Rose MT; Slack A; Stearnes G; McBryde ES
    PLoS One; 2017; 12(11):e0188631. PubMed ID: 29182688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent Tuberculosis Infection Testing Strategies for HIV-Positive Individuals in Hong Kong.
    Wong NS; Chan KCW; Wong BCK; Leung CC; Chan WK; Lin AWC; Lui GCY; Mitchell KM; Lee SS
    JAMA Netw Open; 2019 Sep; 2(9):e1910960. PubMed ID: 31490541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.
    O'Shea MK; Fletcher TE; Beeching NJ; Dedicoat M; Spence D; McShane H; Cunningham AF; Wilson D
    PLoS One; 2014; 9(5):e97366. PubMed ID: 24816576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priorities for screening and treatment of latent tuberculosis infection in the United States.
    Linas BP; Wong AY; Freedberg KA; Horsburgh CR
    Am J Respir Crit Care Med; 2011 Sep; 184(5):590-601. PubMed ID: 21562129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.
    Pooran A; Booth H; Miller RF; Scott G; Badri M; Huggett JF; Rook G; Zumla A; Dheda K
    BMC Pulm Med; 2010 Feb; 10():7. PubMed ID: 20170555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil.
    Costa AG; Carvalho BKS; Araújo-Pereira M; Ibiapina HNS; Spener-Gomes R; Souza AB; Gomes-Silva A; Andrade AMS; Silva EC; Arriaga MB; Benjamin A; Rocha MS; Moreira ASR; Oliveira JG; Figueiredo MC; Turner MM; Durovni B; Cavalcante S; Kritski AL; Rolla VC; Sterling TR; Andrade BB; Cordeiro-Santos M;
    Microbiol Spectr; 2021 Dec; 9(3):e0116321. PubMed ID: 34851140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.